06 Jul The Australian Financial Review: Local IPO activity hammered by COVID-19; EY crunches the numbers
Atomo is featured in this AFR article on the contraction in Australian IPO activity in 2020. Read the full article > ...
23 Jun ASX: Get to know ASX’s new public company: Atomo Diagnostics Limited (ASX: AT1)
Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
05 Jun Ausbiz: Atomo’s new deal means regional production is ramping up just as the recession hits
Managing Director and CEO, John Kelly talks to Ausbiz about Atomo’s expanded partnership with NG Biotech and securing exclusive rights to market and distribute the COVID-19 antibody test for Australia, NZ and parts of SE Asia. Watch the interview here > ...
10 May Stockhead – Dr Boreham’s Crucible: A simpler device gives Atomo the upper hand in blood-based diagnostics
Stockhead’s Tim Boreham discusses Atomo’s background and history and the benefits of its rapid blood test devices for a range of conditions including COVID-19. Read the full article > ...
08 May Stockhead – ScoPo’s health powerplays: How to invest in COVID-19
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
04 May Lawyers Weekly: Atomo raises $30m in IPO
Lawyers Weekly discusses Atomo Diagnostics’ $30 million IPO and ASX listing as well its integrated rapid diagnostic test (RDT) devices. Read the full article >...
30 Apr Founder and CEO John Kelly interviewed by Peter Switzer
Atomo CEO, John Kelly was interviewed by Peter Switzer on Switzer TV, talking about what makes Atomo’s devices unique, how they can be used to test for COVID-19 and the company’s upcoming key milestones. [embed]https://www.youtube.com/watch?v=XpLiQ6Ujq0c[/embed]...
23 Apr Bloomberg: Biotech Listings Help Prop Up Anemic U.S. IPO Market
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
18 Apr Kalkine Media: Atomo Diagnostics – The Shining IPO on ASX Amid COVID 19?
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
17 Apr WSJ.com: Rapid Coronavirus Test Device Maker’s Shares Soar in IPO
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
17 Apr Founder and CEO John Kelly interviewed by David Koch of Ausbiz
CEO John Kelly speaks to David Koch of Ausbiz about the Atomo’s successful ASX listing and support from blue-chip investors. [embed]https://assets.ausbiz.live/assets/e5a23332-74f7-432d-8e99-23fa1907814b/MP4/vimondio_video_1280x720_2000.mp4[/embed]...
17 Apr The Australian: Coronavirus testing biotech Atomo Diagnostics spikes on ASX debut
An article by Damon Kitney in The Australian discusses how Atomo sharesclosed on their first day of trading on the Australian Securities Exchange at almost double their issue price as investors backed the rollout of its COVID-19 rapid testing equipment. Read the full article > ...
17 Apr Biotech Daily: Atomo IPO Opens Up 95% With 1m Covid-19 Antibody Test Orders
A feature in Biotech Daily talks about Atomo’s successful listing and the strong interest in the use of its integrated rapid test device for the testing of COVID-19 antibodies. Read the full article > ...
16 Apr AAP: COVID-19 testmaker Atomo pops on ASX debut
Founder and CEO John Kelly speaks to AAP about the company’s ASX debut and the company’s unique position to make a major impact within the COVID-19 environment. The article was syndicated across a range of national, metropolitan and regional press, 7 News.com.au, 9Finance and Yahoo7...
16 Apr Atomo’s ASX listing featured across Nine Entertainment press
Atomo’s strong perfromance on its first day of being an ASX listed company was featured in markets blogs in the SMH, The Age, Brisbane Times and WA Today. Read the full article > ...
16 Apr Atomo’s strong start to listed life featured in StartUp Daily
This article in StartUp Daily looks at Atomo’s solid share price gain on its first day of trading and its unusual start to life as a listed company with a virtual bell-ringing ceremony. Read the full article > ...
16 Apr Stockhead: ASX newcomer Atomo Diagnostics breaks IPO drought; surges 125pc on debut
An article in Stockhead talks about how Atomo is focused on commercialising its rapid blood test devices for COVID-19. Read the full article here > ...
16 Apr Trading of shares in Atomo commences on the ASX today
Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Atomo Diagnostics Limited commences on the Australian Securities Exchange (ASX) today under the ticker code AT1. Strong institutional and retail investor demand has led to the company raising...
01 Apr Atomo secures significant European sales agreement and announces the early close of its oversubscribed $30 million Initial Public Offer
Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...
01 Apr SBS World News: Covid-19 testing will soon get easier
Founder and CEO John Kelly speaks to SBS World News about how Atomo Diagostics is using technology from its HIV rapid diagnostic tests (RDTs) to create a product that will test for Covid-19. [embed]https://vimeo.com/402583336[/embed] ...
26 Mar Founder and CEO John Kelly interviewed by Bloomberg on subject of RDTs for coronavirus
Today, Founder and CEO of Atomo Diagnostics, John Kelly, was interviewed by Bloomberg on the subject of rapid diagnostic testing for coronavirus (COVID-19). John Kelly explained how Atomo is working with OEM partners in China, the USA, and Europe to bring to market rapid diagnostic tests...
17 Mar Supplementary IPO Prospectus Issued in Response to Multiple COVID-19 Rapid Blood Test Requests
Today, Atomo Diagnostics announced it was working with potential OEM customers to develop rapid self-tests for COVID-19 that could deliver results to patients in as little as 15 minutes, and be deployed in the field without the need for expensive laboratory equipment or extensive clinical...
09 Jul Mylan HIV Self Test receives prequalification approval by WHO
Today, Atomo Diagnostics and partner Mylan have jointly announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO PQ). The WHO PQ process includes a rigorous evaluation of the test’s...
29 Apr Atomo partners with Access Bio to develop the world’s first integrated hepatitis C rapid test for self-testing
Today, in a joint press release, Access Bio Inc. and Atomo Diagnostics have announced the development of a best-in-class rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). It is expected that the new self-tests, along with a professional use version, will be made...
29 Nov Atomo HIV Self Test approved by TGA
Today, Atomo Diagnostics announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA). It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator. Addressing the media following the announcement, Founder and CEO of Atomo Diagnostics,...
24 Sep Strategic Partnership with Mylan NV Announced Today
Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The self-tests, which use the innovative AtomoRapid platform, will allow individuals to confidently screen themselves...
05 Jun Strategic Partnership Announcement: Atomo Diagnostics and Owen Mumford
Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage...
20 Feb New partnership anticipated to transform the diagnosis of febrile ARIs at the point-of-care
Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at...
23 Jan Strategic Partnership Announcement: Atomo Diagnostics and Access Bio
Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets. Atomo will supply its award-winning AtomoRapid™ lateral flow diagnostic test platforms for use with Access Bio’s in vitro HIV rapid...
06 Dec Atomo HIV Self Test approved by Expert Review Panel
Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined by Unitaid and The Global Fund to expedite access to innovative diagnostic products in advance...
- 1
- 2